CPhI Worldwide, organized by UBM (part of Informa PLC), announced the finalists of the 2018 CPhI Pharma Awards. This year’s edition features over 250 entries from 174 participating companies across 17 categories, commending the innovations, technologies, and strategies driving pharma forward.
With 139 shortlisted-chemistry, single-use technologies, drug delivery devices, contract services, and packaging among them-the winners will be announced during a live awards ceremony taking place at the Eurostars Madrid Tower Hotel on October 9-the opening day of CPhI Worldwide.
To see the complete list of finalists, please visit: https://awards.cphi.com/finalists/.
The awards will be presented at the CPhI Awards Gala. For more information visit:https://awards.cphi.com/attend-the-gala/.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
AbbVie’s Emraclidine Fails to Reduce Schizophrenia Symptoms Compared to Placebo
November 11th 2024Results from the Phase II EMPOWER trial found that emraclidine failed to meet its primary endpoint of reducing Positive and Negative Syndrome Scale scores after six weeks of treatment for schizophrenia.